Senores Pharmaceuticals IPO allotment likely on December 26; Find out why the GMP surged over 50%

Senores Pharmaceuticals IPO closes on December 24. The company aimed to raise Rs 582.11 crore. It was subscribed to a total of 36.99 times as of 1330 IST on December 24. The retail portion was booked 69.87 times while the NIIs subscribed to the issue 65.54 times. The QIBs booked the issue 11.47 times. The IPO shares are likely to be listed on NSE and BSE on December 30. Here’s what GMP suggests about the listing gains:

Senores Pharmaceuticals IPO GMP

The company’s shares were attracting a premium of 59% in the grey market. This indicates that the shares might list around a price of Rs 621. The grey market is an unofficial palace to trade shares ahead of listing. Market participants keep an eye on GMP to track listing gains. 

Senores Pharmaceuticals’ financial performance

The company experienced a notable increase in both net profit and revenue in comparison to the past three years. Its net profit came in at Rs 32.7 crore, a jump of 289% year-on-year in FY24, compared with Rs 8.4 crore in FY23. Its revenue from operations stood at Rs 214.5 crore in FY24, a jump 6 times on year, against Rs 35.3 crore in FY23. 

Also ReadCarraro India Vs Senores Pharmaceuticals IPO: Which is a better bet?

Senores Pharmaceuticals IPO details

The issue is a combination of fresh shares and an offer for sale. The allotment of shares is expected to be finalised on December 26. The company set the IPO price band between Rs 372 to Rs 391 per equity share. Equirus Capital, Ambit, and Nuvama Wealth Management are the book-running lead managers of the IPO, while Link Intime India is the registrar for the issue.

Senores Pharmaceuticals IPO review

“With a presence in 43 countries, the company focuses on critical care injectables, APIs, and complex speciality pharmaceutical products. At the upper price band, the company is valued at a P/E of 55x with a market cap of Rs 1800.6 crore post-issue of equity shares and a return on net worth of 23.6% based on FY24. On the valuation front, we believe that the company is fairly priced. Therefore, we recommend a “Subscribe” rating to the IPO,” said Anand Rathi Research in an IPO note.

 » Read More

Related Articles

JB Pharma is riding the CDMO Opportunity. Jefferies reiterates buy…

Jefferies has maintained a Buy on JB Pharma with a revised target price of Rs 2,310. The stock currently trades at Rs 1,714/share implying an 34% upside. This new target price is just a shade lower than the previous target price of Rs 2,340. According to Jefferies, an international brokerage house, the growth drivers are

Two banking stocks to watch ahead of the RBI Policy

By Kiran Jani Bank Nifty reached its all-time high of 54,467 in September 2024. Following this peak, the index experienced a correction, dipping to 47,844 in January 2025—a decline of 7.29%. Despite this pullback, Kotak Bank and ICICI Bank showed relative resilience, delivering returns of 1.61% and -4.20%, respectively, during the same period. Source: Investing.com

New Tax Regime: These deductions, exemptions still available for you

The Indian government introduced a new tax regime in 2020, offering lower tax rates while removing several exemptions and deductions available under the old system. Initially optional, this regime became the default in 2023, requiring taxpayers to opt out if they wished to continue under the old structure. Despite the removal of many benefits, certain

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

JB Pharma is riding the CDMO Opportunity. Jefferies reiterates buy…

Jefferies has maintained a Buy on JB Pharma with a revised target price of Rs 2,310. The stock currently trades at Rs 1,714/share implying an 34% upside. This new target price is just a shade lower than the previous target price of Rs 2,340. According to Jefferies, an international brokerage house, the growth drivers are

Two banking stocks to watch ahead of the RBI Policy

By Kiran Jani Bank Nifty reached its all-time high of 54,467 in September 2024. Following this peak, the index experienced a correction, dipping to 47,844 in January 2025—a decline of 7.29%. Despite this pullback, Kotak Bank and ICICI Bank showed relative resilience, delivering returns of 1.61% and -4.20%, respectively, during the same period. Source: Investing.com

New Tax Regime: These deductions, exemptions still available for you

The Indian government introduced a new tax regime in 2020, offering lower tax rates while removing several exemptions and deductions available under the old system. Initially optional, this regime became the default in 2023, requiring taxpayers to opt out if they wished to continue under the old structure. Despite the removal of many benefits, certain

Range bound session: Nifty ends above 23,600, Sensex holds 78,000 led by Adani Ports, Infosys

The stock markets faced a downturn on Thursday, with major indices closing in the red. The BSE Sensex dropped by 213.12 points or 0.27%, ending the day at 78,058.16, while the NSE Nifty 50 saw a decline of 70.15 points, down by 0.3%, and closed at 23,626.15. The Nifty Bank index also ended the day

IT stocks stable as Cognizant raises annual and quarterly revenue guidance

Shares of Indian IT companies are in the spotlight today after the Nasdaq-listed IT services major Cognizant Technology Solutions, reported its Q4 results that exceeded Wall Street expectations. The Nifty IT Index as well as individual tech counters like Infosys, Wipro, Tech Mahindra and HCL Tech are all in the green even as the markets